loading
Precedente Chiudi:
$2.03
Aprire:
$2.04
Volume 24 ore:
117.08K
Relative Volume:
0.86
Capitalizzazione di mercato:
$68.98M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-1.5272
EPS:
-1.3423
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
-0.49%
1M Prestazione:
-14.94%
6M Prestazione:
-21.15%
1 anno Prestazione:
-36.92%
Intervallo 1D:
Value
$1.99
$2.07
Intervallo di 1 settimana:
Value
$1.94
$2.2199
Portata 52W:
Value
$1.90
$4.21

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
Nome
Vistagen Therapeutics Inc
Name
Telefono
650-577-3600
Name
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
48
Name
Cinguettio
@vistagen
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
VTGN's Discussions on Twitter

Confronta VTGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.05 68.98M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-12-07 Aggiornamento Jefferies Hold → Buy
2023-08-07 Aggiornamento Maxim Group Hold → Buy
2022-07-22 Downgrade Jefferies Buy → Hold
2022-07-22 Downgrade Robert W. Baird Outperform → Neutral
2022-07-22 Downgrade William Blair Outperform → Mkt Perform
2021-05-20 Iniziato Robert W. Baird Outperform
2021-02-18 Iniziato Jefferies Buy
2021-01-04 Aggiornamento William Blair Mkt Perform → Outperform
2018-06-27 Iniziato Maxim Group Buy
2018-02-08 Reiterato Chardan Capital Markets Buy
2017-03-28 Iniziato Maxim Group Buy
Mostra tutto

Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie

pulisher
Jun 18, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise

Jun 17, 2025
pulisher
Jun 17, 2025

Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassi - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen (VTGN) Reports Decrease in FY25 Revenue, Advances Key Medical Programs | VTGN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics, Inc. SEC 10-K Report - TradingView

Jun 17, 2025
pulisher
Jun 16, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Holdings Increased by Millennium Management LLC - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Vistagen Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView

Jun 13, 2025
pulisher
Jun 12, 2025

Vistagen Earnings Preview: Late-Stage Neuroscience Biotech to Unveil FY2025 Performance - Stock Titan

Jun 12, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Has $405,000 Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Acquires New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Earnings Preview: What to Expect from $VTGN Amid Shifting Investor Sentiment | VTGN Stock - paginasiete.bo

Jun 07, 2025
pulisher
Jun 07, 2025

VISTAGEN THERAPEUTICS Earnings Preview: Recent $VTGN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Jun 07, 2025
pulisher
Jun 07, 2025

Vistagen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Jun 07, 2025
pulisher
Jun 05, 2025

VistaGen at Jefferies: Expanding Horizons in Social Anxiety Treatment By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 04, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN St - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - MarketScreener

Jun 02, 2025
pulisher
Jun 02, 2025

Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat

May 31, 2025
pulisher
May 28, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise

May 28, 2025
pulisher
May 28, 2025

Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 23, 2025

Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference - BioSpace

May 23, 2025
pulisher
May 19, 2025

Ellis Martin Report: Vistagen Therapeutics Inc. (NASDAQ:VTGN) CEO Shawn SinghA Revolutionary Fast Acting Nasal Spray Targeting Social Anxiety Disorder - ABN Newswire

May 19, 2025
pulisher
May 12, 2025

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq

May 12, 2025
pulisher
May 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat

May 11, 2025
pulisher
May 08, 2025

254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat

May 08, 2025
pulisher
May 06, 2025

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

May 06, 2025
pulisher
May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025
pulisher
May 04, 2025

Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

May 04, 2025
pulisher
Apr 29, 2025

JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Apr 29, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Apr 24, 2025
pulisher
Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace

Apr 17, 2025
pulisher
Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Capitalizzazione:     |  Volume (24 ore):